NCT05146245招募中4 期
Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 入组人数
- 140
- 试验地点
- 1
- 主要终点
- BMI z-score
研究概览
简要总结
The aim of this study is to test whether therapeutic drug monitoring of risperidone in children with autism spectrum disorder and comorbid behavioral problems is able to reduce metabolic side effect burden, while retaining clinical effectiveness.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 6 to 18 years
- •Documented clinical diagnosis of autism spectrum disorder according to DSM IV or DSM V and comorbid behavioural problems
- •To start treatment with risperidone
排除标准
- •Diabetes type I or II
- •Congenital or acquired syndrome associated with changes in appetite, body weight or lipid profile (e.g. Prader Willi)
- •Treatment with antipsychotic medication within the last 6 months
- •Known Long QT syndrome (LQTS)
- •Pregnancy
结局指标
主要结局
BMI z-score
时间窗: 6 months
Difference in body mass index z-scores 6 months after start of treatment.
次要结局
- Metabolic side effects (triglycerides)(6 months)
- Metabolic side effects (glucose)(6 months)
- Endocrine side effects (prolactin)(6 months)
- Endocrine side effects (ghrelin)(6 months)
- Metabolic side effects (cholesterol)(6 months)
- Extrapyramidal symptoms (EPS)(6 months)
- Endocrine side effects (leptin)(6 months)
- Effectivity (ABC)(6 months)
- Effectivity (CGI)(6 months)
- Quality of Life (PedsQL)(6 months)
- Side effects (blood pressure)(6 months)
研究者
Birgit Koch
Prof.Dr.
Erasmus Medical Center
研究点 (1)
Loading locations...
相似试验
Unknown
不适用
Pharmacological Treatment of Children and Adolescents With Severe Mood DysregulationSevere Mood DysregulationNCT00825552Federal University of Rio Grande do Sul20
已完成
1 期
Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)Child Development Disorders, PervasiveNCT00147394Children's Hospital Medical Center, Cincinnati100
已完成
3 期
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With DementiaAlzheimer DiseaseDementia, VascularDementiaNCT00253123Janssen, LP626
已完成
3 期
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With DementiaAlzheimer DiseaseDementia, VascularDementiaNCT00249145Janssen Pharmaceutica N.V., Belgium349
已完成
3 期
A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled ChildrenLearning DisordersChild Behavior DisordersNCT00254930Janssen-Cilag Ltd.19